Philadelphia CRO Indipharm acquired by PE fund
Velocity Fund Partners has acquired the Philadelphia clinical contract research organisation (CRO) Indipharm and is relaunching the CRO as InClinica. Financial terms of the deal have not been disclosed. Velocity Fund Partners targets promising life sciences opportunities and believes InClinica is well-positioned for growth. “InClinica’s existing global footprint and experience